Ratings Hims & Hers Health, Inc.

Equities

HIMS

US4330001060

Real-time Estimate Cboe BZX 10:10:15 2024-03-28 am EDT 5-day change 1st Jan Change
15.9 USD +0.98% Intraday chart for Hims & Hers Health, Inc. -4.66% +79.21%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company does not generate enough profits, which is an alarming weak point.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 202.65 times its estimated earnings per share for the ongoing year.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

1st Jan change Capi. Investor Rating ESG Refinitiv
+79.21% 3.37B -
+41.33% 603M -
+42.77% 470M - -
-42.52% 249M
C-
-20.86% 96.86M -
C-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock
  2. Equities
  3. Stock Hims & Hers Health, Inc. - Nyse
  4. Ratings Hims & Hers Health, Inc.